Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Heidi M. Namløs, Tale Barøy, Else Munthe, Skyler Mishkin, Susanne Lorenz, Eva W. Stratford, Leonardo A. Meza-Zepeda, Kjetil Boye, Ola Myklebost, Brian Kudlow, Bodil Bjerkehagen
Publikováno v:
Molecular Cancer Therapeutics. 17:2473-2480
Molecular analysis of circulating tumor DNA (ctDNA) has a large potential for clinical application by capturing tumor-specific aberrations through noninvasive sampling. In gastrointestinal stromal tumor (GIST), analysis of KIT and PDGFRA mutations is
Autor:
Tobias Herold, Luise Hartmann, Wolfgang Hiddemann, Philipp A. Greif, Daniela Schumacher, Bianka Ksienzyk, Claudia D. Baldus, Bernhard Wörmann, Evelyn Zellmeier, Stephan Wolf, Sebastian Vosberg, Friederike Pastore, Helmut Blum, Stephanie Schneider, Sophie M. Stief, Stefanos A. Bamopoulos, Wolfgang E. Berdel, Ines Hellmann, Stefan Krebs, Alexander Graf, Karsten Spiekermann, Klaus H. Metzeler, Stefan K. Bohlander, Vindi Jurinovic, Nikola P. Konstandin, Raphael Mattes, Dennis Görlich, Martin Neumann, Kathrin Bräundl, Paul Kerbs
Publikováno v:
Clinical Cancer Research. 24:1716-1726
Purpose: To study mechanisms of therapy resistance and disease progression, we analyzed the evolution of cytogenetically normal acute myeloid leukemia (CN-AML) based on somatic alterations. Experimental Design: We performed exome sequencing of matche
Autor:
Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics. 16:555-565
MET or hepatocyte growth factor (HGF) receptor pathway signaling mediates wound healing and hepatic regeneration, with pivotal roles in embryonic, neuronal, and muscle development. However, dysregulation of MET signaling mediates proliferation, apopt
Autor:
Stephen N. Thibodeau, Michelle R. Mahoney, Richard M. Goldberg, Harry H. Yoon, Daniel J. Sargent, Thomas C. Smyrk, Steven R. Alberts, Frank A. Sinicrope, Garth D. Nelson
Publikováno v:
Clinical Cancer Research. 21:5294-5304
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (ex
Autor:
Maria E. Arcila, Efsevia Vakiani, Jaclyn F. Hechtman, Jason T. Huse, Jinru Shia, Laetitia Borsu, Rona Yaeger, Justyna Sadowska, Marc Ladanyi
Publikováno v:
Molecular Cancer Research. 13:1003-1008
The PI3K/AKT/mTOR pathway is activated through multiple mechanisms in colorectal carcinoma. Here, the clinicopathologic and molecular features of AKT1 E17K–mutated colorectal carcinoma in comparison with PIK3CA-mutated colorectal carcinoma are desc
Autor:
Chang-Qi Zhu, Melania Pintilie, Desmond She, Frances A. Shepherd, Shingo Sakashita, David W. Cescon, Ming-Sound Tsao
Publikováno v:
Clinical Cancer Research. 21:2499-2505
Purpose: Genomic profiling of lung squamous cell carcinomas (SCC) has identified NRF2 pathway alterations, which activate oxidative response pathways, in one third of tumors. Preclinical data suggest these tumors may be resistant to platinum-based ch
Autor:
Anne de la Rochefordière, Ivan Bièche, Virginie Fourchotte, Florence Joly, Emmanuel Sevin, Béatrice Weber, Mathieu Minsat, Benard Asselain, Anne Floquet, Maud Kamal, Suzy Scholl, Maud Aumont, Quentin Leroy, Laurence Thomas, Marius Pop, Alhassane Diallo, Sophie Maillard, Hervé Curé, Michel Fabbro, Peter Petrow, Philippe Beuzeboc, Thierry Petit, K. Peignaux, Laurence Gladieff, Corine Plancher, Laurence Gonzague, Virginie Bernard, Claire Brunaud, Christine Kerr, Dominique Berton-Rigaud, AnaTereza Nadan, Sebastien Armanet, Audrey Margogne
Publikováno v:
Clinical Cancer Research. 21:2530-2537
Purpose: EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcino
Autor:
Chen Jiang, Alan P. Venook, Alexander B. Sibley, Ivo D. Shterev, Kouros Owzar, Herbert Hurwitz, Stephanie M. Cushman, Andrew B. Nixon, Donna Niedzwiecki, Ace J. Hatch
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 5
Purpose: Formalin-fixed, paraffin-embedded tumor samples from CALGB 80203 were analyzed for expression of EGFR axis–related genes to identify prognostic or predictive biomarkers for cetuximab treatment. Patients and Methods: Patients (238 total) wi